CN113302191A - 取代的咪唑并吡啶化合物的结晶形式及其作为p2x3调节剂的用途 - Google Patents

取代的咪唑并吡啶化合物的结晶形式及其作为p2x3调节剂的用途 Download PDF

Info

Publication number
CN113302191A
CN113302191A CN201980088914.9A CN201980088914A CN113302191A CN 113302191 A CN113302191 A CN 113302191A CN 201980088914 A CN201980088914 A CN 201980088914A CN 113302191 A CN113302191 A CN 113302191A
Authority
CN
China
Prior art keywords
crystalline form
methyl
compound
mammal
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980088914.9A
Other languages
English (en)
Chinese (zh)
Inventor
D·加索
罗伯特·M·文斯洛
K·帕伊扎
N·乔雷特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 3 Ltd
Original Assignee
Bellus Health Cough Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bellus Health Cough Inc filed Critical Bellus Health Cough Inc
Publication of CN113302191A publication Critical patent/CN113302191A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
CN201980088914.9A 2018-11-13 2019-11-12 取代的咪唑并吡啶化合物的结晶形式及其作为p2x3调节剂的用途 Pending CN113302191A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862760307P 2018-11-13 2018-11-13
US62/760,307 2018-11-13
PCT/IB2019/001199 WO2020099923A1 (en) 2018-11-13 2019-11-12 Crystalline forms of a substituted imidazopyridine compound and use thereof as p2x3 modulator

Publications (1)

Publication Number Publication Date
CN113302191A true CN113302191A (zh) 2021-08-24

Family

ID=70732059

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980088914.9A Pending CN113302191A (zh) 2018-11-13 2019-11-12 取代的咪唑并吡啶化合物的结晶形式及其作为p2x3调节剂的用途

Country Status (20)

Country Link
US (1) US20220002292A1 (https=)
EP (1) EP3880678B1 (https=)
JP (2) JP2022507251A (https=)
CN (1) CN113302191A (https=)
AU (1) AU2019378161B2 (https=)
CA (1) CA3119711A1 (https=)
DK (1) DK3880678T3 (https=)
ES (1) ES3033466T3 (https=)
FI (1) FI3880678T3 (https=)
HR (1) HRP20250864T1 (https=)
HU (1) HUE071480T2 (https=)
IL (1) IL282996A (https=)
LT (1) LT3880678T (https=)
MX (1) MX2021005424A (https=)
PL (1) PL3880678T3 (https=)
PT (1) PT3880678T (https=)
RS (1) RS66922B1 (https=)
SI (1) SI3880678T1 (https=)
SM (1) SMT202500237T1 (https=)
WO (1) WO2020099923A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113727716A (zh) * 2019-02-25 2021-11-30 贝卢斯医疗咳嗽病公司 采用p2x3调节剂的治疗

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL282087B2 (en) * 2018-10-10 2025-11-01 Bellus Health Cough Inc 4-(imidazo[1,2-a]pyridin-3-yl)-benzamide derivatives for treating pruritus
CN114085220B (zh) * 2020-06-22 2023-06-16 上海海雁医药科技有限公司 取代的吗啉-4-羧酸酯衍生物、其组合物及医药上的用途
EP4169921A4 (en) * 2020-06-29 2024-06-19 Wuhan LL Science and Technology Development Co., Ltd. Crystalline form of heterocyclic compound, preparation method therefor and application thereof
WO2022161462A1 (zh) * 2021-01-29 2022-08-04 上海海雁医药科技有限公司 吗啉衍生物及其药物组合物和用途
WO2025140586A1 (zh) * 2023-12-29 2025-07-03 人福医药集团股份公司 一种p2x3受体拮抗剂的固体分散体及其制备工艺
WO2025191081A1 (en) 2024-03-15 2025-09-18 Glaxosmithkline Intellectual Property (No.3) Limited Crystalline form of camlipixant
WO2025210540A1 (en) 2024-04-02 2025-10-09 Assia Chemical Industries Ltd. Solid state forms of camlipixant and process for preparation thereof
WO2026022326A1 (en) * 2024-07-25 2026-01-29 Glaxosmithkline Intellectual Property (No.3) Limited P2x3 antagonist formulation
JP2026049185A (ja) 2024-09-06 2026-03-18 キヤノン株式会社 撮像装置、撮像方法、及びコンピュータプログラム

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105246888A (zh) * 2013-01-31 2016-01-13 尼奥迈德研究所 咪唑并吡啶化合物及其用途
US10111883B1 (en) * 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105246888A (zh) * 2013-01-31 2016-01-13 尼奥迈德研究所 咪唑并吡啶化合物及其用途
US10111883B1 (en) * 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
吕阳 杜冠华 主编: "药物晶型", vol. 2, 人民卫生出版社, pages: 1 - 12 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113727716A (zh) * 2019-02-25 2021-11-30 贝卢斯医疗咳嗽病公司 采用p2x3调节剂的治疗

Also Published As

Publication number Publication date
PT3880678T (pt) 2025-05-22
MX2021005424A (es) 2021-06-15
EP3880678A1 (en) 2021-09-22
JP2022507251A (ja) 2022-01-18
AU2019378161A1 (en) 2021-06-03
SI3880678T1 (sl) 2025-08-29
EP3880678A4 (en) 2022-08-31
AU2019378161B2 (en) 2025-01-30
LT3880678T (lt) 2025-06-25
HRP20250864T1 (hr) 2025-09-26
EP3880678B1 (en) 2025-05-07
HUE071480T2 (hu) 2025-08-28
RS66922B1 (sr) 2025-07-31
WO2020099923A1 (en) 2020-05-22
FI3880678T3 (fi) 2025-08-01
IL282996A (en) 2021-06-30
US20220002292A1 (en) 2022-01-06
PL3880678T3 (pl) 2025-08-04
DK3880678T3 (da) 2025-06-10
JP2024153665A (ja) 2024-10-29
SMT202500237T1 (it) 2025-07-22
CA3119711A1 (en) 2020-05-22
ES3033466T3 (en) 2025-08-04

Similar Documents

Publication Publication Date Title
CN113302191A (zh) 取代的咪唑并吡啶化合物的结晶形式及其作为p2x3调节剂的用途
JP7350117B2 (ja) Ｍａｇｌ阻害剤の結晶形態
US20230339957A1 (en) Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
EP3102213B1 (en) Pharmaceutical compositions for the treatment of inflammatory disorders
CN107530348B (zh) 一种含有jak激酶抑制剂或其可药用盐的药物组合物
CN101686976B (zh) 含有4,5-环氧基吗啡喃衍生物的稳定的固体制剂
JP2025026857A (ja) 痛風または高尿酸血症を処置または予防するための化合物の結晶形態
JP2022510303A (ja) 痛風または高尿酸血症を処置または予防するための方法
CN115279347A (zh) Ahr抑制剂和其用途
MX2011013091A (es) Un antagonista del receptor de trombina y tableta con dosificacion fija de clopidogrel.
WO2020000831A1 (zh) 一种酮咯酸氨丁三醇片剂
AU2020289738A1 (en) A pharmaceutical composition comprising an oxazine derivative and its use in the treatment or prevention of Alzheimer's Disease
JP2025524598A (ja) Ｓ１ｐ受容体モジュレーターの結晶形態
EP3675865B1 (en) Crystalline forms of compounds for preventing or treating sensory hair cell death
JP7608444B2 (ja) インドールアミン２，３－ジオキシゲナーゼ阻害剤の医薬製剤
WO2026085383A1 (en) Crystalline forms of an nlrp3 modulator
CN119816502A (zh) Tyk2抑制剂的结晶形式
CN112057428A (zh) 一种酒石酸伐尼克兰的药物组合物及其制备方法
CN112057431A (zh) 一种酒石酸伐尼克兰片剂及其制备方法
HK1244704B (zh) 一种含有jak激酶抑制剂或其可药用盐的药物组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20240605

Address after: Kaisan ohokkatsu

Applicant after: Silvio Berlusconi health Co.

Country or region after: Canada

Address before: Kaisan ohokkatsu

Applicant before: Bellus medical cough Co.

Country or region before: Canada

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240614

Address after: Kaisan ohokkatsu

Applicant after: 14245563 Canada Inc.

Country or region after: Canada

Address before: Kaisan ohokkatsu

Applicant before: Silvio Berlusconi health Co.

Country or region before: Canada

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240704

Address after: Kaisan ohokkatsu

Applicant after: ID BIOMEDICAL CORPORATION OF QUEBEC

Country or region after: Canada

Address before: Kaisan ohokkatsu

Applicant before: 14245563 Canada Inc.

Country or region before: Canada

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240716

Address after: Steve Niki

Applicant after: GlaxoSmithKlay Intellectual Property (No.3) Co.,Ltd.

Country or region after: Britain

Address before: Kaisan ohokkatsu

Applicant before: ID BIOMEDICAL CORPORATION OF QUEBEC

Country or region before: Canada

TA01 Transfer of patent application right